Bristol close to selling diabetes stake to Astra for $3 billion: WSJ

Wed Dec 18, 2013 7:26pm EST

Related Topics

(Reuters) - Bristol-Myers Squibb Co is close to selling its stake in a diabetes partnership with AstraZeneca Plc to the British drugmaker in a deal valued at more than $3 billion, the Wall Street Journal reported on Wednesday.

Bristol had announced last month that it would no longer conduct research to discover new drugs for diabetes, hepatitis C and neurological conditions, but would increase spending on medicines that harness the immune system to fight cancer.

That refocus led to speculation that Bristol would seek to sell its share in the non-U.S. part of the diabetes joint venture to AstraZeneca.

Bristol spokeswoman Laura Hortas declined to comment on the reported deal. Officials at AstraZeneca did not immediately respond to requests for comment.

The joint venture includes the oral medicines Onglyza, Kombiglyze and Forxiga, as well as the injectable treatments Bydureon and Byetta.

Demand for many of these products has been relatively slow to build up and Forxiga, also known as dapagliflozin, was rejected by U.S. regulators in 2012.

(Reporting by Deena Beasley; Editing by Phil Berlowitz)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (1)
This is precisely why the focus must be shifted from treatment of acute cases to prevention of metabolic syndrome, or pre Diabetes, from evolving into Type 2 Diabetes. Drugs are not the answer to this challenge.
Type 2 Diabetes is fundamentally a lifestyle related condition that can be prevented. The most important preventatives are:
1. Diet – Low carbs, Very little or no refined sugar, no high fructose corn syrup, heaps of fruit, little or no processed foods, low saturated fat.
2. Chemo preventative dietary supplements. Transmax and Bioforte Resveratrol have been conclusively shown to lower blood glucose and blood pressure, improve insulin sensitivity, and help to keep one’s weight in check. These supplements are also effective as a treatment when administered to patients who are and are not taking the Metformin type drugs. Ask your endocrinologists. He should be familiar with Transmax. Given the mass of peer reviewed evidence in the public domain, any physician who does not consider Transmax or Bioforte for his Type 2 Diabetes patient is negligent.
3. Exercise and weight control. Obesity is the prime cause of Diabetes.
If the patient waits until he has Type 2 Diabetes to think about prevention he/she will be facing a lifetime of drugs, disability, and eventual loss of sight and possible limb amputations from its complications.

Dec 19, 2013 10:45am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.